WO1985004589A1 - Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs - Google Patents
Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs Download PDFInfo
- Publication number
- WO1985004589A1 WO1985004589A1 PCT/US1985/000596 US8500596W WO8504589A1 WO 1985004589 A1 WO1985004589 A1 WO 1985004589A1 US 8500596 W US8500596 W US 8500596W WO 8504589 A1 WO8504589 A1 WO 8504589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- steroidal anti
- ibuprofen
- acid derivative
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates generally to novel pharmaceutical compositions of matter comprising one or more non-steroidal anti-inflammatory drugs (NSAID) in combination with at least one antihistamine, sympathomimetic drug (nasal decongestant, bronchodilator) cough suppressant and/or expectorant, optionally in combination with suitable pharmaceutically acceptable non-toxic carriers or excipients, and to methods of using said compositions in the treatment, management or mitigation of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith.
- NSAID non-steroidal anti-inflammatory drugs
- Non-narcotic analgesics most of which are also known as non-steroidal anti-inflammatory drugs
- NSAID non-narcotic analgesic class of drugs
- Aspirin and acetaminophen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- symptom alleviating compositions.
- non-narcotic agents offering a variety of advantages over these conventionally employed non-narcotic analgesic anti-pyretics.
- the principal advantages of these non-steroidal anti-inflammatory drugs include not only the clinically superior analgesic, anti-inflammatory and antipyretic activity of these agents compared to aspirin, acetaminophen or phenacetin, but also a minimization of the adverse side affects experienced with these conventional agents; more specifically, the gastrointestinal ulcerations experienced with aspirin and the hepatic toxicity prevalent with the chronic use of acetaminophen.
- Exemplary prior art cough/cold formulations containing aspirin or acetaminophen include Coricidin ® , Coricidin D ® , Comtrex ® , Dristan ® , Daycare ® , Cotylenol ® , Sinubid ® and the like. These formulations generally contain in addition to aspirin or acetaminophen, one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.
- compositions of matter comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug (NSAID) in combination with at least one of an antihistamine, decongestant, cough suppressant, expectorant and, optionally, including pharmaceutically acceptable carriers therefor.
- NSAID non-steroidal anti-inflammatory drug
- Cold-like symptoms refers to coryza, nasal congestion, upper respiratory infections, allergic rhinitis, otitis, sinusitis, etc.
- Another object of the present invention is to provide suitable dosage unit forms of one or more NSAID' s in combination with at least one of the aforementioned antihistamines, decongestants, etc. adapted for convenient oral administration.
- non-steroidal anti-inflammatory agents are ideally suited for use in cough/cold formulations by reason of their enhanced analgesic anti-inflammatory and antipyretic activity and low incidence of untoward side effects, particularly at the optimum dosages provided for in the present invention, compared to aspirin or acetaminophen.
- Naproxen sodium 550 mg was compared with 650 mg of aspirin and was found to provide earlier and better pain relief than aspirin by Sevelius, H. , J. Clin. Pharmacol. 20; 480-485. 1980. "Comparative Analgesic Effects of Naproxen Sodium, Aspirin and Placebo. "
- Flurbiprofen 50 and 100 mg was significantly more effective than aspirin 600 mg.
- Flurbiprofen 25 mg was slightly less effective than aspirin 600 mg.
- NSAID' s non-steroidal anti-inflammatory drugs
- pharmaceutical compositions and methods of use of the present invention may be selected from any of the following categories:
- NSAID any non-narcotic analgesic non-steroidal anti-inflammatory compound, including the pharmaceutically acceptable non-toxic salts thereof, falling within one of the five structural categories above but excluding aspirin, acetaminophen and phenacetin.
- the specific compounds falling within the foregoing definition of the non-steroidal anti-inflammatory drugs for use in the present invention are well known to those skilled in the art and reference may be had to various literature reference sources for their chemical structures, pharmacological activities, side effects, normal dosage ranges, etc. See, for example.
- propioni ⁇ acid derivatives for use herein, ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen, and fluprofen may be mentioned as particularly preferred compounds.
- acetic acid derivatives Of the acetic acid derivatives, presently preferred members include tolmetin sodium, zomepirac, sulindac and indomethacin.
- fenamic acid derivatives particularly preferred compounds include mefenamic acid and meclofenamate sodium.
- the particularly preferred biphenylcarboxylic acid derivatives for use in the present invention include diflunisal and flufenisal.
- the particularly advantageous oxicams include piroxicam, sudoxicam and isoxicam.
- any of the foregoing compounds may be utilized in the form of their pharmaceutically acceptable salt forms, e.g., -COO-Na + , -COO-K + , and the like.
- ibuprofen and naproxen are most preferred.
- typical effective analgesic amounts of presently preferred NSAID's for use in unit dose compositions of the invention are about 100 - 500 mg diflunisal, about 25 - 100 mg zomepirac sodium, about 50-400 mg ibuprofen, most preferably 100-200 mg, about 125-500 mg naproxen, about 25-100 mg flurbiprofen, about 50-100 mg fenoprofen, about 10-20 mg piroxicam, about 125-250 mg mefenamic acid, about 100-400 mg fenbufen or about 25-50 mg ketoprofen; however, greater or lesser amounts may be employed if desired or necessary.
- suitable dosage ranges for these compounds will generally
- NSAID' s including acceptable analgesically effective amounts thereof for use in unit dose compositions of the present invention also appears in applicants United States Patent No. 4,486,436.
- the cough/cold pharmaceutical compositions of the present invention comprise, in addition to the non-steroidal anti-inflammatory drugs, at least one active ingredient from the following pharmacological classes: antihistamines, sympathomimetics (decon gestants) , cough suppressants-antitussives and expectorants.
- Typical therapeutically active components from these categories, along with their usual adult dosage, for use in the pharmaceutical compositions and methods of the invention are set forth in the following Table 1.
- mice Blue Spruce Farm male mice weighing 18-28 grams at the time of testing are used throughout. All mice are dosed orally by gavage with ibuprofen and/or diphenhydramine.
- the formulation of each test article is a solution or suspension in 0.25% methylcellulose manufactured by Fisher Scientific Company. A dosing volume of 10 ml/mg is used. All doses are coded and the test is performed under a code not known to the observer. Doses are based upon the weights of the animal taken prior to dosing.
- mice METHOD A phenylquinone writhing assay in mice was conducted over a four day period to test for synergism of the analgesic activity of ibuprofen and diphenhydramine.
- the assay consists of phenyl-p-benzoquinone (PPQ) introduced in mice thirty minutes post dose of the test treatment (s) .
- the PPQ is prepared as a .02% aqueous solution in 5 ml ethyl alcohol q.s. to 100 ml with distilled water and is administered intraperitoneally at .25 ml/mouse.
- the mice are injected with the PPQ solution and are placed in individual plastic squares 4"x4"x5" deep and observed for a ten minute period post treatment dose for exhibition of the writhing syndrome. Complete blocking of the writhing syndrome for the ten minute observation period in any one mouse is considered a positive response for that mouse. Conversely, if the mouse definitely writhes at least once, it is considered to be not protected from the PPQ.
- mice Three hundred twenty-eight mice were randomly assigned to 40 groups. Two groups of ten mice per series were assigned to a control group (10 prior to the administration of the test treatments and 10 post administration) to verify the ability of the solutions to produce the writhing response.
- the purpose of the assay on the first day is to estimate the ED 50 (effective dose in 50% of treated mice) of ibuprofen alone and of diphenhydramine alone, and to estimate the relative potency, , of ibuprofen to diphenhydramine, determined as the ratio of the ED 50 of ibuprofen to the ED 50 of diphenhydramine.
- Eight mice per group are dosed orally (via intubation) with 2, 5, 10 and 20 mg/kg of ibuprofen and 5, 10, 20 and 50 mg/kg of diphenhydramine.
- Table 2 shows the number of mice protected from writhing activity for each dose of ibuprofen and diphenhydramine.
- the method of Finney ["Statistical Method of Biological Assay", McMillan
- Table 3 shows for each of these combination doses, the number of mice protected from writhing activity.
- the first combination treatment used a ratio of ibuprofen to diphenhydramine of 19:8 and the doses of the constituent drugs in mg/kg that were studied were (8,3) , (12,5), (16,7) and (28,12).
- the second combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 6:28 and the doses of the constituent drugs in mg/kg that were studied were (3,14), (4.5,21) and (9,42) .
- the third combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 9:24 and the doses of the constituent drugs in mg/kg that were studied were (3,8), (6,16), (12,32) and (15,40).
- the fourth combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 4:32 and the doses of the constituent drugs in mg/kg that were studied were (3,24), (3.5,28) (4.5,36) and (5,40).
- each dose of each combination is equivalent to a dose of ibuprofen, based on the relative potency ( ⁇ ) of diphenhydramine to ibuprofen obtained from the experiment on the first day.
- the combination of 28 mg/kg of ibuprofen and 12 mg/kg of diphenhydramine is, under the assumption of additivity, equivalent to (28+12 ⁇ ) mg/kg of ibuprofen.
- Table 4 shows for each dose of each of the combination doses tested the number of mice observed to be protected and the ibuprofen equivalent dose.
- ED 50 's were estimated based on the observed number of mice protected at each ibuprofen equivalent dose using the method of Finney.
- Table 5 displays the estimated ED 50 's for each ratio.
- the surprising synergistic effects of combining ibuprofen with diphenhydramine can be seen from the results of Tables 4 and 5 and the Figure of Drawing.
- the Figure of Drawing summarizes all of the findings by depicting the ED 50 's obtained for each treatment alone, the ED 50 line if the treatments were additive, the number of mice/protected from writhing for each treatment studied and the estimated ED 50 's for each combination ratio.
- the ED 50 of ibuprofen alone is estimated to be 24 mg/kg and for diphenhydramine to be 38 mg/kg.
- the relative potency of diphenhydramine to ibuprofen is 24/38.
- synergism appears to be present for four ratios, and these ratios were further investigated on days 3 and
- the ED 50 's were found to be for the dosage ratio of 19:8, 23 mg/kg of ibuprofen, for the dosage ratio 6:28, 19 mg/kg of ibuprofen, for the dosage ratio 9:24, 18 mg/kg of ibuprofen, and for the dosage ratio 4:32, 23 mg/kg of ibuprofen.
- Two of these ED 50 's are substantially less than 24 mg/kg of ibuprofen which is the ED 50 that would be expected if the effects were additive. This represents a 25% reduction of the amount of ibuprofen that is required to obtain the effect in 50% of the animals.
- the Figure of Drawing indicates that many other dose ratios as well would produce an unexpected synergistic effect.
- the foregoing active ingredients will be combined with the non-steroidal anti-inflammatory drug(s) and will typically be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules, elixirs, syrups, etc. and consistent with conventional pharmaceutical practices.
- carrier suitable pharmaceutical diluents, excipients or carriers
- the active drug components may be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol (liquid forms) and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated in the mixture.
- suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
- lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, etc.
- Disintegrators include, without limitation, starch, methylcellulose, agar, bentonite, guar gum, etc. Sweetening and flavoring agents and preservatives can also be included where appropriate.
- compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components to optimize the therapeutic effects, i.e., analgesia, antihistaminic, etc. while minimizing undesirable side effects.
- Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
- Triturate active ingredients and q.s. with lactose to selected capsule size Triturate active ingredients and q.s. with lactose to selected capsule size
Abstract
Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.
Description
COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Background of the Invention The present invention relates generally to novel pharmaceutical compositions of matter comprising one or more non-steroidal anti-inflammatory drugs (NSAID) in combination with at least one antihistamine, sympathomimetic drug (nasal decongestant, bronchodilator) cough suppressant and/or expectorant, optionally in combination with suitable pharmaceutically acceptable non-toxic carriers or excipients, and to methods of using said compositions in the treatment, management or mitigation of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith.
Non-narcotic analgesics, most of which are also known as non-steroidal anti-inflammatory drugs
(NSAID) , are widely administered orally in the treatment of mild to severe pain. Within this class, the compounds vary widely in their chemical structure and in their biological profiles as analgesics, anti-inflammatory agents and antipyretic agents. Among the most commonly used members of the non-narcotic analgesic class of drugs are aspirin, acetaminophen and phenacetin. Aspirin and acetaminophen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- symptom alleviating compositions.
However, a number of alternative non-narcotic agents offering a variety of advantages over these conventionally employed non-narcotic analgesic anti-pyretics have now been developed. The principal advantages of these non-steroidal anti-inflammatory
drugs include not only the clinically superior analgesic, anti-inflammatory and antipyretic activity of these agents compared to aspirin, acetaminophen or phenacetin, but also a minimization of the adverse side affects experienced with these conventional agents; more specifically, the gastrointestinal ulcerations experienced with aspirin and the hepatic toxicity prevalent with the chronic use of acetaminophen.
Exemplary prior art cough/cold formulations containing aspirin or acetaminophen include Coricidin®, Coricidin D®, Comtrex®, Dristan®, Daycare®, Cotylenol®, Sinubid® and the like. These formulations generally contain in addition to aspirin or acetaminophen, one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.
While aspirin and acetaminophen have been utilized in these previous compositions, it has not been heretofore proposed to use any of the newer non-steroidal anti-inflammatory drugs (i.e., excluding aspirin, acetaminophen and phenacetin) in the preparation of advantageous cough/cold pharmaceutical compositions.
Summary of the Invention It is, therefore, a primary object of the present invention to provide pharmaceutical compositions of matter comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug (NSAID) in combination with at least one of an antihistamine, decongestant, cough suppressant, expectorant and, optionally, including pharmaceutically acceptable carriers therefor.
It is a further object of the present invention to provide methods for the symptomatic relief
of cough, cold, cold-like and flu symptoms by the administration of preselected dosages of the pharmaceutical compositions of the present invention. Cold-like symptoms as used herein refers to coryza, nasal congestion, upper respiratory infections, allergic rhinitis, otitis, sinusitis, etc.
Another object of the present invention is to provide suitable dosage unit forms of one or more NSAID' s in combination with at least one of the aforementioned antihistamines, decongestants, etc. adapted for convenient oral administration.
Brief Description of the Drawing The Figure of Drawing is a plot of dose of diphenhydramine versus dose of ibuprofen in the phenylquinone writhing assay to indicate the number of mice protected.
Detailed Description of the Invention More specifically, the applicants herein have found that certain non-steroidal anti-inflammatory agents are ideally suited for use in cough/cold formulations by reason of their enhanced analgesic anti-inflammatory and antipyretic activity and low incidence of untoward side effects, particularly at the optimum dosages provided for in the present invention, compared to aspirin or acetaminophen.
The superiority of various of the non-narcotic analgesics belonging to the non-steroidal anti-inflammatory drug class in comparative studies with aspirin and acetaminophen is well documented in the literature.
Cooper in 1977 found that ibuprofen 400 mg had a greater peak effect and longer duration of action
than aspirin 650 mg. Cooper, S.A., Needle, A.E., Kruger, G.O. 1977. "An Analgesic Relative Potency Assay Comparing Aspirin, Ibuprofen and Placebo. "J. Oral Surg. 35;898-903. Cooper in another study in 1982 found 400 mg of ibuprofen to be more effective than aspirin 650 mg. Cooper, S.A., Engel, J., Ladov, M. , Precheur, H., Rosenheck, A., Rauch, D. 1982. "Analgesic Efficacy of an Ibuprofen-codeine Combination." Pharmacotherapy 2;162-67. Sunshine et al found ibuprofen to be significantly superior to aspirin in the relief of post-episiotomy pain. Sunshine, A. et al. Clinical Pharmacology and Therapeutics, :24;254-250, 1983.
Dionne in 1982 found ibuprofen to be more effective than acetaminophen in delaying the onset and intensity of post-operative dental pain. Dionne, R.A., Campbell, R.A., Cooper, S.A., Hall, D.L., Buckingham, B. "Suppression of Post operative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen and Acetaminophen Plus Codeine." J. Clin. Phamacol. (In press) .
Naproxen sodium 550 mg was compared with 650 mg of aspirin and was found to provide earlier and better pain relief than aspirin by Sevelius, H. , J. Clin. Pharmacol. 20; 480-485. 1980. "Comparative Analgesic Effects of Naproxen Sodium, Aspirin and Placebo. "
Flurbiprofen 50 and 100 mg was significantly more effective than aspirin 600 mg. Flurbiprofen 25 mg was slightly less effective than aspirin 600 mg.
Sunshine, A., Olson N.Z., Laska, E.M. Zighelboim, I., DeCastro, A., Desarrazin, C. , Pharmaco Ther.3:177-181. " Analgesic Effect of Graded Doses of Flurbiprofen in Postepisiotomy Pain".
Silberman found suprofen 200 mg more effective than aspirin 650 mg for pain relief in the treatment of moderate to severe pain resulting from musculoskeletal pain. Silberman, H.M. "Multiple-Dose Comparison of Suprofen, Aspirin and Placebo in the
Treatment of Musculoskeletal Pain." Pharmacology 27 :S 1, 65-73 (1983).
While these reported findings with respect to the outstanding analgesic properties of the non- steroidal anti-inflammatory drugs compared to aspirin or acetaminophen have prompted the widespread acceptance and usage of these newer non-narcotic analgesics, as single entities, for the treatment and management of acute and chronic inflammatory states, notably rheumatoid arthritis and osteoarthritis, the utilization of these agents in cough/cold compositions has not heretofore been considered.
The non-steroidal anti-inflammatory drugs (NSAID' s) for use in the pharmaceutical compositions and methods of use of the present invention may be selected from any of the following categories:
(1) The propionic acid derivatives;
(2) The acetic acid derivatives;
(3) The fenamic acid derivatives; (4) The biphenylcarboxylic acid derivatives; and
(5) The oxicams.
Accordingly, the term "NSAID" as used herein is intended to mean any non-narcotic analgesic non-steroidal anti-inflammatory compound, including the pharmaceutically acceptable non-toxic salts thereof, falling within one of the five structural categories above but excluding aspirin, acetaminophen and phenacetin.
The specific compounds falling within the foregoing definition of the non-steroidal anti-inflammatory drugs for use in the present invention are well known to those skilled in the art and reference may be had to various literature reference sources for their chemical structures, pharmacological activities, side effects, normal dosage ranges, etc. See, for example. Physician's Desk Reference, 35th Edition, 1981 and The Merck Index, 9th Edition, Merck and Company, Rahway, New Jersey (1976) and Cutting's Handbook of Pharmacology, 6th Edition, Ed. T. Z. Czacky, M.D. , Appleton-Century-Crofts, New York, 1979, Chapter 49:538-550.
Of the propioniσ acid derivatives for use herein, ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen, and fluprofen may be mentioned as particularly preferred compounds.
Of the acetic acid derivatives, presently preferred members include tolmetin sodium, zomepirac, sulindac and indomethacin.
Of the fenamic acid derivatives, particularly preferred compounds include mefenamic acid and meclofenamate sodium.
The particularly preferred biphenylcarboxylic acid derivatives for use in the present invention include diflunisal and flufenisal.
The particularly advantageous oxicams include piroxicam, sudoxicam and isoxicam.
Of course, it will be appreciated by those skilled in the art, that any of the foregoing compounds may be utilized in the form of their pharmaceutically acceptable salt forms, e.g., -COO-Na+, -COO-K+, and the like.
Of the foregoing non-steroidal anti- inflammatory drugs, in the practice of the preferred embodiments of the present invention, ibuprofen and naproxen are most preferred. With respect to the dosage amount of the non-steroidal anti-inflammatory drugs in the compositions of the invention, although the specific dose will vary depending upon the age and weight of the patient, the severity of the symptoms, the incidence of side effects and the like, for humans, typical effective analgesic amounts of presently preferred NSAID's for use in unit dose compositions of the invention are about 100 - 500 mg diflunisal, about 25 - 100 mg zomepirac sodium, about 50-400 mg ibuprofen, most preferably 100-200 mg, about 125-500 mg naproxen, about 25-100 mg flurbiprofen, about 50-100 mg fenoprofen, about 10-20 mg piroxicam, about 125-250 mg mefenamic acid, about 100-400 mg fenbufen or about 25-50 mg ketoprofen; however, greater or lesser amounts may be employed if desired or necessary. With respect to the compounds set forth hereinabove falling within the propionic acid derivative category, suitable dosage ranges for these compounds will generally fall within the range of 25 mg to 600 mg in each unit dose. A complete description of the various
NSAID' s, including acceptable analgesically effective amounts thereof for use in unit dose compositions of the present invention also appears in applicants United States Patent No. 4,486,436. The cough/cold pharmaceutical compositions of the present invention comprise, in addition to the non-steroidal anti-inflammatory drugs, at least one active ingredient from the following pharmacological classes: antihistamines, sympathomimetics (decon
gestants) , cough suppressants-antitussives and expectorants. Typical therapeutically active components from these categories, along with their usual adult dosage, for use in the pharmaceutical compositions and methods of the invention are set forth in the following Table 1.
Among such Table 1 antihistamines, sympathomimetics, cough suppressants-antitussives and expectorants, in combination with a non-steroidal anti-inflammatory drug, applicants have already demonstrated a synergistically enhanced analgesic and anti-inflammatory response in a mammalian organism, as shown below in Example 1.
Example 1 - Pharmacologic Test for Synergism - Ibuprofen/Diphenhydramine.
The unexpected synergistic analgesic effect of the addition of diphenhydramine to ibuprofen is evidenced by tests conducted on mice. Blue Spruce Farm male mice weighing 18-28 grams at the time of testing are used throughout. All mice are dosed orally by gavage with ibuprofen and/or diphenhydramine. The formulation of each test article is a solution or suspension in 0.25% methylcellulose manufactured by Fisher Scientific Company. A dosing volume of 10 ml/mg is used. All doses are coded and the test is performed under a code not known to the observer. Doses are based upon the weights of the animal taken prior to dosing.
METHOD A phenylquinone writhing assay in mice was conducted over a four day period to test for synergism of the analgesic activity of ibuprofen and diphenhydramine.
The assay consists of phenyl-p-benzoquinone (PPQ) introduced in mice thirty minutes post dose of the test treatment (s) . The PPQ is prepared as a .02%
aqueous solution in 5 ml ethyl alcohol q.s. to 100 ml with distilled water and is administered intraperitoneally at .25 ml/mouse. The mice are injected with the PPQ solution and are placed in individual plastic squares 4"x4"x5" deep and observed for a ten minute period post treatment dose for exhibition of the writhing syndrome. Complete blocking of the writhing syndrome for the ten minute observation period in any one mouse is considered a positive response for that mouse. Conversely, if the mouse definitely writhes at least once, it is considered to be not protected from the PPQ.
Three hundred twenty-eight mice were randomly assigned to 40 groups. Two groups of ten mice per series were assigned to a control group (10 prior to the administration of the test treatments and 10 post administration) to verify the ability of the solutions to produce the writhing response.
The purpose of the assay on the first day is to estimate the ED50 (effective dose in 50% of treated mice) of ibuprofen alone and of diphenhydramine alone, and to estimate the relative potency, , of ibuprofen to diphenhydramine, determined as the ratio of the ED50 of ibuprofen to the ED50 of diphenhydramine. Eight mice per group are dosed orally (via intubation) with 2, 5, 10 and 20 mg/kg of ibuprofen and 5, 10, 20 and 50 mg/kg of diphenhydramine. Table 2 shows the number of mice protected from writhing activity for each dose of ibuprofen and diphenhydramine. The method of Finney ["Statistical Method of Biological Assay", McMillan
Pub., 3rd Edition, 1978] is used to estimate the ED50's of ibuprofen alone and diphenhydramine alone.
On the second day eight combination doses were studied. The doses were chosen based upon the
ED50's established in the preceding day's experiment, which, under the assumption of additivity, would provide protection for 50% of the mice. These doses were tested in order to observe those ratio (s) of the combination drugs that would yield a synergistic effect. Combinations for which five or more mice exhibit blockage of writhing are candidates for further study. The doses of the constituent drugs in mg/kg for the eight groups were for ibuprofen (I) and diphenhydramine (D) respectively, [abbreviated as (I,D)]: (22,4), (19,8), (16,12), (14,6), (11,20), (9,24), (6,28), (4,32). Table 3 shows for each of these combination doses, the number of mice protected from writhing activity. On the third and fourth days the four specific fixed ratios that achieved 5 or more protected mice were studied in more detail, i.e., the first combination treatment used a ratio of ibuprofen to diphenhydramine of 19:8 and the doses of the constituent drugs in mg/kg that were studied were (8,3) , (12,5), (16,7) and (28,12). The second combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 6:28 and the doses of the constituent drugs in mg/kg that were studied were (3,14), (4.5,21) and (9,42) . The third combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 9:24 and the doses of the constituent drugs in mg/kg that were studied were (3,8), (6,16), (12,32) and (15,40). The fourth combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 4:32 and the doses of the constituent drugs in mg/kg that were studied were (3,24), (3.5,28) (4.5,36) and (5,40).
Under the assumption of additivity each dose of each combination is equivalent to a dose of
ibuprofen, based on the relative potency (ρ) of diphenhydramine to ibuprofen obtained from the experiment on the first day. Thus, for example, in the dose ratio 19:8 the combination of 28 mg/kg of ibuprofen and 12 mg/kg of diphenhydramine is, under the assumption of additivity, equivalent to (28+12ρ) mg/kg of ibuprofen. Table 4 shows for each dose of each of the combination doses tested the number of mice observed to be protected and the ibuprofen equivalent dose. For each of the four combination ratios, ED50's were estimated based on the observed number of mice protected at each ibuprofen equivalent dose using the method of Finney. Table 5 displays the estimated ED50's for each ratio.
RESULTS
The surprising synergistic effects of combining ibuprofen with diphenhydramine can be seen from the results of Tables 4 and 5 and the Figure of Drawing. The Figure of Drawing summarizes all of the findings by depicting the ED50's obtained for each treatment alone, the ED50 line if the treatments were additive, the number of mice/protected from writhing for each treatment studied and the estimated ED50's for each combination ratio. The ED50 of ibuprofen alone is estimated to be 24 mg/kg and for diphenhydramine to be 38 mg/kg. The relative potency of diphenhydramine to ibuprofen is 24/38. Among the 8 ratios tested on the second day, synergism appears to be present for four ratios, and these ratios were further investigated on days 3 and
4. The ED50's were found to be for the dosage ratio of 19:8, 23 mg/kg of ibuprofen, for the dosage ratio 6:28, 19 mg/kg of ibuprofen, for the dosage ratio 9:24, 18
mg/kg of ibuprofen, and for the dosage ratio 4:32, 23 mg/kg of ibuprofen. Two of these ED50's are substantially less than 24 mg/kg of ibuprofen which is the ED50 that would be expected if the effects were additive. This represents a 25% reduction of the amount of ibuprofen that is required to obtain the effect in 50% of the animals. The Figure of Drawing indicates that many other dose ratios as well would produce an unexpected synergistic effect.
In the pharmaceutical compositions and methods of the present invention, the foregoing active ingredients will be combined with the non-steroidal anti-inflammatory drug(s) and will typically be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules, elixirs, syrups, etc. and consistent with conventional pharmaceutical practices. For instance, for oral administration in the form of tablets or capsules, the active drug components may be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated in the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, etc. Disintegrators include, without limitation, starch, methylcellulose, agar, bentonite, guar gum, etc. Sweetening and flavoring agents and preservatives can also be included where appropriate.
Of course, additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components to optimize the
therapeutic effects, i.e., analgesia, antihistaminic, etc. while minimizing undesirable side effects. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
As representative suitable formulations consistent with the objects, features and advantages of the present invention, the following non-limiting examples are provided.
Example 2
Ibuprofen - 200 mg Chlorpheniramine maleate - 8 mg
Phenylpropanolamine hydrochloride - 8 mg Dextromethorphan hydrobromide - 30 mg Guaifenesin - 100 mg
Triturate active ingredients and q.s. with lactose to selected capsule size
Example 3
In each fluid ounce:
Naproxen (sodium) 250 mg, dextromethorphan HB 30 mg, phenylpropanolamine hydrochloride 25 mg, orange flavoring and alcohol 10% v/v.
From the foregoing, other typical acceptable pharmaceutical formulations will be apparent to those skilled in the art of pharmaceutical formulations.
While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit of the invention. For example, effective dosages other than the preferred ranges set forth hereinabove with respect to the active ingredients may be applicable as a consequence of variations of the responsiveness of the mammal treated, severity of symptoms, dosage related adverse effects, if any, observed and similar considerations. Accordingly, such expected variations or differences in the practice of the present invention and the results obtained are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore that the invention be limited only by the scope of the claims which follow.
Claims
1. In a pharmaceutical composition comprising an analgesic in combination with at least one of an antihistamine, decongestant, cough suppressant or expectorant, the improvement comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug or pharmaceutically acceptable salt thereof as the analgesic component.
2. A composition according to Claim 1, wherein said non-steroidal anti-inflammatory drug is selected from a propionic acid derivative, an acetic acid derivative, a fenamic acid derivative, a biphenylcarboxylie acid derivative, an oxicam or the pharmaceutically acceptable salts thereof.
3. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug comprises a propionic acid derivative selected from ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, trioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, or bucloxic acid.
4. A composition according to Claim 3, wherein said drug is ibuprofen or naproxen.
5. A composition according to Claim 3, wherein said analgesically effective amount of said drug comprises between about 50 mg to 600 mg in each unit dose thereof.
6. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug comprises an acetic acid derivative selected from indomethacin, sulindac, tolmetin, zomepirac, diclofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac or oxpinac.
7. A composition according to Claim 6 wherein said analgesiσally effective amount of said drug ranges between about 25 to 400 mg in each unit dose thereof.
8. A composition according to Claim 2 wherein said fenamic acid derivative is selected from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid or tolfenamic acid.
9. A composition according to Claim 8, wherein said analgesically effective amount of said drug ranges between about 250 to 500 mg in each unit dose thereof.
10. A composition according to Claim 2 wherein said non-steroidal anti-inflammatory drug comprises a biphenylcarboxylic acid derivative selected from diflunisal or flufenisal.
11. A composition according to Claim 10, wherein said analgesiσally effective amount of said drug ranges between about 250 to 500 mg in each unit dose thereof.
12. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug com prises an oxicam selected from piroxicam, sudoxicam, or isoxicam.
13. A composition according to Claim 12 wherein said analgesically effective amount of said drug ranges between about 10 to 20 mg in each unit dose thereof.
14. A composition of matter according to Claim 1, wherein said antihistamine is selected from chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, diphenhydramine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenydramine, phenyltoloxamine, phenindamine, pyrilamine or azatadine.
15. A composition according to Claim 1 wherein said decongestant is selected from pseudoephedrine, phenylpropanolamine, or phenylephrine.
16. A composition according to Claim 1 wherein said cough suppressant is selected from caramiphen, dextromethorphan or codeine.
17. A composition according to Claim 1 wherein said expectorant is selected from terpin hydrate, guaifenesin, potassium iodide, potassium citrate or potassium guaiacolsulfonate.
18. A composition according to Claim 1 further comprising a pharmaceutically acceptable non-toxic carrier.
19. A composition according to Claim 18 adapted for oral administration in tablet, capsule or liquid form.
20. A method of alleviating cough, cold and cold-like symptoms in a mammal in need thereof, comprising administering thereto a symptom alleviating amount of a composition according to Claim 1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT85901895T ATE72989T1 (en) | 1984-04-09 | 1985-04-08 | COUGH AND/OR COLD MIXTURES CONTAINING NON-STEROID ANTI-INFLAMMATORY MEDICATIONS. |
DE8585901895T DE3585495D1 (en) | 1984-04-09 | 1985-04-08 | MIXTURES AGAINST Cough and / or Colds Containing Non-Steroids Anti-Inflammatory Drugs. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/598,502 US4552899A (en) | 1984-04-09 | 1984-04-09 | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US598,502 | 1984-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985004589A1 true WO1985004589A1 (en) | 1985-10-24 |
Family
ID=24395811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1985/000596 WO1985004589A1 (en) | 1984-04-09 | 1985-04-08 | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
Country Status (9)
Country | Link |
---|---|
US (11) | US4552899A (en) |
EP (1) | EP0180597B1 (en) |
JP (1) | JP2848556B2 (en) |
AT (1) | ATE72989T1 (en) |
AU (2) | AU589554B2 (en) |
CA (1) | CA1258430A (en) |
DE (1) | DE3585495D1 (en) |
WO (1) | WO1985004589A1 (en) |
ZA (1) | ZA852485B (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0241615A1 (en) * | 1986-04-15 | 1987-10-21 | Warner-Lambert Company | A pharmaceutical composition of phenindamine having enhanced release characteristics |
EP0295212A2 (en) * | 1987-06-10 | 1988-12-14 | Warner-Lambert Company | Process for preparing a pharmaceutical composition |
EP0316434A1 (en) * | 1987-06-08 | 1989-05-24 | Abraham Sunshine | Cough/cold mixtures comprising non-sedating antihistamine drugs. |
EP0348683A1 (en) * | 1988-06-01 | 1990-01-03 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine |
EP0384514A2 (en) * | 1989-02-21 | 1990-08-29 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
WO1991000088A1 (en) * | 1989-06-23 | 1991-01-10 | Boehringer Ingelheim France | Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents |
EP0413171A1 (en) * | 1989-08-17 | 1991-02-20 | Dolorgiet GmbH & Co. KG | Strong analgesic composition and process for its preparation |
WO1992004021A1 (en) * | 1990-09-11 | 1992-03-19 | Richardson Vicks Inc. | Method for providing improved analgesic effect |
WO1992004022A1 (en) * | 1990-09-11 | 1992-03-19 | Richardson Vicks Inc. | Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders |
WO1992015332A1 (en) * | 1991-03-04 | 1992-09-17 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
US5164398A (en) * | 1991-04-01 | 1992-11-17 | Merck & Co., Inc. | Ibuprofen-antitussive combinations |
EP0566393A1 (en) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
WO1994014476A1 (en) * | 1992-12-21 | 1994-07-07 | The Procter & Gamble Company | Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders |
WO1994018970A1 (en) * | 1993-02-18 | 1994-09-01 | Warner-Lambert Company | Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents |
EP0631782A1 (en) * | 1993-06-30 | 1995-01-04 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine |
WO1995004058A1 (en) * | 1993-07-29 | 1995-02-09 | Les Laboratoires Meram | 2-(3-benzoylphenyl)propionic acid codeine salt, preparation method therefor and pharmaceutical compositions containing said salt |
WO1997004808A1 (en) * | 1995-07-28 | 1997-02-13 | The Procter & Gamble Company | Compositions containing analgesics and antihistamines and methods for treating respiratory disorders |
WO1997006801A1 (en) * | 1995-08-18 | 1997-02-27 | Parke Davis | Composition containing mefenamic acid in association with codeine |
FR2741264A1 (en) * | 1995-11-16 | 1997-05-23 | Parke Davis | Compsn. contg. fenamic acid deriv. and codeine |
US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
WO1998048839A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
WO1999066919A1 (en) * | 1998-06-19 | 1999-12-29 | Mcneil-Ppc, Inc. | Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient |
WO2001070205A2 (en) * | 2000-03-23 | 2001-09-27 | Smithkline Beecham P.L.C. | Composition comprising paracetamol and niflumic acid |
WO2001074341A2 (en) * | 2000-03-30 | 2001-10-11 | Schering Corporation | Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
EP1255544A1 (en) * | 2000-01-31 | 2002-11-13 | Magainin Pharmaceuticals, Inc. | Mucin synthesis inhibitors |
WO2002096406A1 (en) * | 2001-05-25 | 2002-12-05 | Ssp Co., Ltd. | Medicinal compositions |
WO2003068203A1 (en) * | 2002-01-30 | 2003-08-21 | Zentiva, A.S. | Use of a combination of a non-steroidal anti-inflammatory agent and guaifenesin for the treatment of acute pain |
WO2004058236A1 (en) * | 2002-12-20 | 2004-07-15 | Pediamed Pharmaceuticals, Inc. | Compositions and methods for treating upper respiratory congestion |
EP1572206A2 (en) * | 2002-12-18 | 2005-09-14 | Wyeth | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
EP2050435A1 (en) | 2007-10-18 | 2009-04-22 | Renate Conrad | Cough mixture |
GB2475359A (en) * | 2009-11-11 | 2011-05-18 | Biocopea Ltd | A compound for use in treating a fulminant respiratory disorder |
US8304405B2 (en) | 2002-06-14 | 2012-11-06 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
WO2016063057A1 (en) * | 2014-10-21 | 2016-04-28 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
WO2017062997A1 (en) * | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
WO2022119431A1 (en) * | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4783465A (en) * | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4662880A (en) * | 1986-03-14 | 1987-05-05 | Alza Corporation | Pseudoephedrine, brompheniramine therapy |
US5260333A (en) * | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
GB8629567D0 (en) * | 1986-12-10 | 1987-01-21 | Boots Co Plc | Therapeutic agents |
US4810502A (en) * | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
US5023076A (en) * | 1987-02-27 | 1991-06-11 | Alza Corporation | Lamina comprising carboxyvinyl polymer |
US4915952A (en) * | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US4861797A (en) * | 1987-10-15 | 1989-08-29 | Oratech Pharmaceutical Development Corporation | Liquid ibuprofen compositions and methods of making them |
US4859704A (en) * | 1987-10-15 | 1989-08-22 | Oratech Pharmaceutical Development Corporation | Water soluble ibuprofen compositions and methods of making them |
US4883818A (en) * | 1987-11-17 | 1989-11-28 | Analgesic Associates | Onset-hastened/enhanced analgesia |
US4927854A (en) * | 1987-12-24 | 1990-05-22 | Analgesic Associates | Sustained/enhanced analgesia |
US5286751A (en) * | 1987-12-24 | 1994-02-15 | Analgesic Associates | Sustained/enhanced antipyretic response |
US4826903A (en) * | 1988-02-22 | 1989-05-02 | Eastman Kodak Company | Condensation polymer containing the residue of an acyloxystyrl compound and shaped articles produced therefrom |
US4933172A (en) * | 1988-10-06 | 1990-06-12 | Warner-Lambert Co. | Method of and compositions for treating destructive periodontal disease |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
US5134165A (en) * | 1989-06-09 | 1992-07-28 | Hirsch Kauffmann Dan J | Method of treatment for loss of vision due to ophthalmic surgery |
US5580577A (en) * | 1990-01-11 | 1996-12-03 | Herzenberg; Leonard A. | Method of treating the symptoms of human rhinovirus infection |
US5036067A (en) * | 1990-03-14 | 1991-07-30 | Merck & Co., Inc. | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
US5260073A (en) * | 1990-05-21 | 1993-11-09 | Norwich Eaton Pharmaceuticals, Inc. | Use of phenylpropanolamine as a mucus secretogogue in the upper airways |
US5175152A (en) * | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
US5179097A (en) * | 1991-06-10 | 1993-01-12 | Angres Isaac A | Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids |
ZA933725B (en) * | 1992-05-28 | 1993-12-15 | Elan Corp Plc | Tablet formulation |
PT815860E (en) † | 1992-08-03 | 2006-08-31 | Sepracor Inc | TERFENADINE CARBOXYLATE AND TREATMENT OF ALLERGIC DISORDERS. |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
EP0692975A4 (en) * | 1993-04-08 | 2000-11-29 | Univ Queensland | Administration of vaso-active agent and therapeutic agent |
US5451401A (en) * | 1993-09-29 | 1995-09-19 | The Procter & Gamble Company | Diphosphonic acid esters as tartar control agents |
ATE259232T1 (en) * | 1995-03-03 | 2004-02-15 | Endo Pharmaceuticals Inc | USE OF DEXTROMETHORPHAN OR DEXTRORPHANE TO TREAT URINARY INCONTINENCE |
US5840731A (en) * | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
US5648358A (en) * | 1996-03-05 | 1997-07-15 | Mitra; Sekhar | Compositions and methods for treating respiratory disorders |
US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5998478A (en) * | 1997-01-15 | 1999-12-07 | Platt; Chris E. | Timed release tablet comprising naproxen and pseudoephedrine |
US5859060A (en) * | 1997-01-15 | 1999-01-12 | Platt; Chris | Timed release tablet comprising naproxen and pseudoepherine |
RS49982B (en) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
US6194431B1 (en) * | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
US6037358A (en) * | 1999-03-24 | 2000-03-14 | Carter-Wallace, Inc. | Decongestant/antihistaminic compositions |
US6211246B1 (en) * | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
US6100274A (en) * | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
US20040234457A1 (en) * | 1999-10-19 | 2004-11-25 | The Procter & Gamble Company | Methods of preventing and treating SARS using low pH respiratory tract compositions |
US20040033260A1 (en) * | 1999-10-19 | 2004-02-19 | The Procter & Gamble Company | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
US6114346A (en) | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
SK287684B6 (en) | 1999-12-20 | 2011-06-06 | Schering Corporation | Sustained release solid oral pharmaceutical dosage composition |
SK287105B6 (en) | 1999-12-20 | 2009-12-07 | Schering Corporation | Bilayer sustained release oral dosage composition |
US6099860A (en) * | 2000-01-21 | 2000-08-08 | Platt; Chris E. | Controlled release oral preparation with naproxen sodium and pseudoephedrine |
US20020147216A1 (en) * | 2000-01-31 | 2002-10-10 | Yuhong Zhou | Mucin synthesis inhibitors |
US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
SE0000773D0 (en) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
SE0000774D0 (en) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US6586469B2 (en) | 2000-07-25 | 2003-07-01 | Medpointe Healthcare Inc. | Antihistaminic/antitussive compositions |
WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US6566396B2 (en) | 2000-11-30 | 2003-05-20 | Medpointe Healthcare Inc. | Antitussive/antihistaminic compositions |
US20020177626A1 (en) | 2001-01-19 | 2002-11-28 | Cook Graham D. | Treatment of sleep disturbances |
US7273623B2 (en) * | 2001-10-12 | 2007-09-25 | Kiel Laboratories, Inc. | Process for preparing tannate tablet, capsule or other solid dosage forms |
US6869618B2 (en) | 2001-04-10 | 2005-03-22 | Kiel Laboratories, Inc. | Process for preparing tannate liquid and semi-solid dosage forms |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
JP4756823B2 (en) * | 2001-06-01 | 2011-08-24 | ポーゼン インコーポレイテッド | Pharmaceutical composition for coordinated delivery of NSAIDs |
BR0211794A (en) * | 2001-07-31 | 2004-11-03 | Wyeth Corp | Pharmaceutical composition and method for masking the taste of at least one unpleasant tasting pharmaceutically active compound |
US20030044461A1 (en) * | 2001-08-22 | 2003-03-06 | Carter-Wallace, Inc. | Antitussive/expectorant compositions |
US20030060422A1 (en) | 2001-08-31 | 2003-03-27 | Balaji Venkataraman | Tannate compositions and methods of treatment |
US6509492B1 (en) | 2001-08-31 | 2003-01-21 | First Horizon Pharmaceutical Corporation | Tannate compositions and methods of treatment |
SE0102993D0 (en) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
US20040132827A1 (en) * | 2001-10-26 | 2004-07-08 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
US6827946B2 (en) * | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
CA2469736A1 (en) * | 2002-04-09 | 2003-10-23 | Kiel Laboratories, Inc. | Diphenhydramine tannate solid dose compositions and methods of use |
EA007156B1 (en) | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Sustained release of guaifenesin combination drugs |
US7148376B2 (en) * | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
US20040162273A1 (en) * | 2003-01-23 | 2004-08-19 | The Procter & Gamble Company | Powder pharmaceutical compositions |
EP1628656B1 (en) * | 2003-03-25 | 2008-10-15 | Kiel Laboratories, Inc. | Gabapentin tannate in liquid and/or semi-solid dosage forms |
EP1622603A4 (en) * | 2003-03-25 | 2010-03-24 | Kiel Lab Inc | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
WO2004093866A1 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Process for preparing phenolic acid salts of gabapentin |
US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
GB0312419D0 (en) * | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
US20050037979A1 (en) * | 2003-06-05 | 2005-02-17 | Ping Jeffrey H. | Tannate compositions and methods of use |
US6954474B2 (en) * | 2003-06-27 | 2005-10-11 | Optical Communications Products, Inc. | Method and apparatus for backside monitoring of VCSELs |
US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
US9492541B2 (en) * | 2004-09-14 | 2016-11-15 | Sovereign Pharmaceuticals, Llc | Phenylepherine containing dosage form |
US20050232987A1 (en) * | 2004-03-12 | 2005-10-20 | Viswanathan Srinivasan | Dosage form containing a morphine derivative and another drug |
US20050137262A1 (en) * | 2003-12-22 | 2005-06-23 | Hu Patrick C. | Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
US20070190125A1 (en) | 2004-03-03 | 2007-08-16 | Constantine Georgiades | Positioning feature for aiding use of film or strip product |
US20070110676A1 (en) * | 2005-11-17 | 2007-05-17 | The Procter & Gamble Company | Compositions useful for prevention and treatment of common cold and influenza-like symptoms |
DK2428205T3 (en) | 2006-03-16 | 2012-10-22 | Tris Pharma Inc | MODIFIED FORMULATIONS CONTAINING PHARMACEUTICAL ION EXCHANGE RESIN COMPLEX |
US20080003280A1 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
CL2007002425A1 (en) * | 2006-08-22 | 2008-06-27 | Albermarle Corp | PROCEDURE OF CONTROLLED PREPARATION OF SODIUM SALT OF IBUPROFEN OF SIZE OF MEDIUM PARTICLE; AND SUCH SODIUM SALT PARTICLES. |
CA2669410C (en) | 2006-11-21 | 2015-07-14 | Mcneil-Ppc, Inc. | Modified release analgesic suspensions |
WO2008105920A1 (en) * | 2007-02-28 | 2008-09-04 | Collegium Pharmaceutical, Inc. | Antihistamine combination |
US20080305159A1 (en) * | 2007-06-06 | 2008-12-11 | Mikart, Inc. | Ibuprofen-Hydrocodone-Antihistamine Composition |
US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
AU2008280801B2 (en) * | 2007-07-23 | 2014-03-06 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
KR20110079641A (en) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | Method for delivering a pharmaceutical composition to patient in need thereof |
US7914828B2 (en) * | 2008-10-17 | 2011-03-29 | Levine Brian M | Combination herbal product to benefit respiratory tract |
US8518439B2 (en) * | 2008-12-03 | 2013-08-27 | Novartis Ag | Liquid therapeutic composition |
AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US8957095B2 (en) | 2009-10-26 | 2015-02-17 | Sephoris Pharmaceuticals, Llc | Treatment of sunburn using analgesics and antihistamines |
US8470375B1 (en) | 2010-01-05 | 2013-06-25 | Neos Therapeutics, Lp | Method of formulating and designing liquid drug suspensions containing ion exchange resin particles |
US8361519B2 (en) | 2010-11-18 | 2013-01-29 | Aadvantics Pharmaceuticals, Inc. | Combination herbal product to benefit respiratory tract in people exposed to smoke |
WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
UA115139C2 (en) | 2011-12-28 | 2017-09-25 | Поузен Інк. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
MX2019003039A (en) | 2016-09-26 | 2019-07-08 | Procter & Gamble | Extended relief dosage form. |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4322427A (en) * | 1981-04-16 | 1982-03-30 | Bristol-Myers Company | Analgetic compositions and methods of use |
EP0097953A2 (en) * | 1982-06-30 | 1984-01-11 | E.I. Du Pont De Nemours And Company | Synergistic compositions of nalbuphine and non-narcotic analgesic compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3936528A (en) * | 1974-02-13 | 1976-02-03 | Syntex Corporation | Analgesic formulations having enhanced therapeutic activity |
US4115589A (en) * | 1977-05-17 | 1978-09-19 | The Upjohn Company | Compounds, compositions and method of use |
US4279906A (en) * | 1977-11-10 | 1981-07-21 | Nasa | Indomethacin-antihistamine combination for gastric ulceration control |
US4374836A (en) * | 1978-10-16 | 1983-02-22 | Imperial Chemical Industries Ltd. | Antisecretory heterocyclic derivatives, process for their manufacture and pharmaceutical compositions containing them |
US4230717A (en) * | 1978-12-29 | 1980-10-28 | Lovelace Alan M Administrator | Indomethacin-antihistamine combination for gastric ulceration control |
GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
CA1194799A (en) * | 1981-12-10 | 1985-10-08 | Eric L. Nelson | Method and composition for reducing menstrual pain |
IT1190663B (en) * | 1982-01-21 | 1988-02-24 | Ausonia Farma Srl | COMPOUND WITH ANTI-INFLAMMATORY, ANALGESIC AND MUCOREGULATING ACTIVITY, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
US4447443A (en) * | 1982-11-15 | 1984-05-08 | Merck & Co., Inc. | Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID) |
US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
-
1984
- 1984-04-09 US US06/598,502 patent/US4552899A/en not_active Expired - Lifetime
-
1985
- 1985-04-02 ZA ZA852485A patent/ZA852485B/en unknown
- 1985-04-08 AU AU41200/85A patent/AU589554B2/en not_active Expired
- 1985-04-08 WO PCT/US1985/000596 patent/WO1985004589A1/en not_active Application Discontinuation
- 1985-04-08 DE DE8585901895T patent/DE3585495D1/en not_active Revoked
- 1985-04-08 JP JP60501531A patent/JP2848556B2/en not_active Expired - Lifetime
- 1985-04-08 EP EP85901895A patent/EP0180597B1/en not_active Revoked
- 1985-04-08 AT AT85901895T patent/ATE72989T1/en active
- 1985-04-09 CA CA000478645A patent/CA1258430A/en not_active Expired
- 1985-07-08 US US06/752,546 patent/US4619934A/en not_active Expired - Lifetime
-
1986
- 1986-07-21 US US06/887,205 patent/US4738966A/en not_active Expired - Lifetime
-
1987
- 1987-02-19 US US07/016,377 patent/US4749711A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,344 patent/US4839354A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,397 patent/US4749720A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,563 patent/US4749721A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,396 patent/US4749723A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,333 patent/US4749697A/en not_active Expired - Lifetime
- 1987-02-19 US US07/016,376 patent/US4749722A/en not_active Expired - Lifetime
-
1988
- 1988-01-15 US US07/144,099 patent/US4920149A/en not_active Expired - Lifetime
-
1995
- 1995-05-25 AU AU20291/95A patent/AU2029195A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4322427A (en) * | 1981-04-16 | 1982-03-30 | Bristol-Myers Company | Analgetic compositions and methods of use |
EP0097953A2 (en) * | 1982-06-30 | 1984-01-11 | E.I. Du Pont De Nemours And Company | Synergistic compositions of nalbuphine and non-narcotic analgesic compounds |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Volume 101, Nr. 23, 3 December 1984, (Columbus, Ohio, US) TRABER, DANUEL L.: "Ibuprofen and Diphenhydramine Reduce the Lung Lesion of Endotoxemia in Sheep", page 39, column 1, Abstract Nr. 204101x & J. TRAUMA, 1984, 24 (9), 835-40 see Abstract * |
Unlisted Drugs, Volume 20, Nr. 11, November 1968, (Chatham, New Jersey, US) page 169n "Sinubid" (cited in the application) * |
Unlisted Drugs, Volume 23, Nr. 3, March 1971, (Chatham, New Jersey, US) page 36, "Co-Tylenol" (cited in the application) * |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0241615A1 (en) * | 1986-04-15 | 1987-10-21 | Warner-Lambert Company | A pharmaceutical composition of phenindamine having enhanced release characteristics |
EP0316434A1 (en) * | 1987-06-08 | 1989-05-24 | Abraham Sunshine | Cough/cold mixtures comprising non-sedating antihistamine drugs. |
EP0316434A4 (en) * | 1987-06-08 | 1989-10-16 | Abraham Sunshine | Cough/cold mixtures comprising non-sedating antihistamine drugs. |
EP0295212A2 (en) * | 1987-06-10 | 1988-12-14 | Warner-Lambert Company | Process for preparing a pharmaceutical composition |
EP0295212A3 (en) * | 1987-06-10 | 1990-07-04 | Warner-Lambert Company | Process for preparing a pharmaceutical composition |
EP0348683A1 (en) * | 1988-06-01 | 1990-01-03 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine |
EP0384514A3 (en) * | 1989-02-21 | 1991-04-03 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
EP0384514A2 (en) * | 1989-02-21 | 1990-08-29 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
WO1991000088A1 (en) * | 1989-06-23 | 1991-01-10 | Boehringer Ingelheim France | Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents |
US5173304A (en) * | 1989-08-17 | 1992-12-22 | Dolorgiet Beteiligungs Gmbh | Agents for the treatment of severe pain and preparation of said agents |
EP0413171A1 (en) * | 1989-08-17 | 1991-02-20 | Dolorgiet GmbH & Co. KG | Strong analgesic composition and process for its preparation |
WO1992004021A1 (en) * | 1990-09-11 | 1992-03-19 | Richardson Vicks Inc. | Method for providing improved analgesic effect |
WO1992004022A1 (en) * | 1990-09-11 | 1992-03-19 | Richardson Vicks Inc. | Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders |
WO1992015332A1 (en) * | 1991-03-04 | 1992-09-17 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
US5164398A (en) * | 1991-04-01 | 1992-11-17 | Merck & Co., Inc. | Ibuprofen-antitussive combinations |
EP0566393A1 (en) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
US5739165A (en) * | 1992-04-17 | 1998-04-14 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
WO1994014476A1 (en) * | 1992-12-21 | 1994-07-07 | The Procter & Gamble Company | Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders |
WO1994018970A1 (en) * | 1993-02-18 | 1994-09-01 | Warner-Lambert Company | Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents |
US5726180A (en) * | 1993-06-30 | 1998-03-10 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
US5629316A (en) * | 1993-06-30 | 1997-05-13 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
EP0631782A1 (en) * | 1993-06-30 | 1995-01-04 | Takeda Chemical Industries, Ltd. | Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine |
FR2708611A1 (en) * | 1993-07-29 | 1995-02-10 | Meram Lab | Codeine salt of 2- (3-benzoylphenyl) propionic acid, process for obtaining same and pharmaceutical compositions containing it. |
WO1995004058A1 (en) * | 1993-07-29 | 1995-02-09 | Les Laboratoires Meram | 2-(3-benzoylphenyl)propionic acid codeine salt, preparation method therefor and pharmaceutical compositions containing said salt |
WO1997004808A1 (en) * | 1995-07-28 | 1997-02-13 | The Procter & Gamble Company | Compositions containing analgesics and antihistamines and methods for treating respiratory disorders |
WO1997006801A1 (en) * | 1995-08-18 | 1997-02-27 | Parke Davis | Composition containing mefenamic acid in association with codeine |
FR2741264A1 (en) * | 1995-11-16 | 1997-05-23 | Parke Davis | Compsn. contg. fenamic acid deriv. and codeine |
US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
WO1998048839A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
WO1999066919A1 (en) * | 1998-06-19 | 1999-12-29 | Mcneil-Ppc, Inc. | Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient |
US7504409B2 (en) | 2000-01-31 | 2009-03-17 | Genaera Corporation | Mucin synthesis inhibitors |
EP1255544A1 (en) * | 2000-01-31 | 2002-11-13 | Magainin Pharmaceuticals, Inc. | Mucin synthesis inhibitors |
EP1255544A4 (en) * | 2000-01-31 | 2005-02-02 | Genaera Corp | Mucin synthesis inhibitors |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
US7199153B2 (en) | 2000-03-23 | 2007-04-03 | Smithkline Beechman, P.L.C. | Pharmaceutical composition comprising paracetamol and niflumic acid |
WO2001070205A3 (en) * | 2000-03-23 | 2002-04-04 | Smithkline Beecham Plc | Composition comprising paracetamol and niflumic acid |
WO2001070205A2 (en) * | 2000-03-23 | 2001-09-27 | Smithkline Beecham P.L.C. | Composition comprising paracetamol and niflumic acid |
WO2001074341A3 (en) * | 2000-03-30 | 2002-05-16 | Schering Corp | Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
SG96611A1 (en) * | 2000-03-30 | 2003-06-16 | Schering Corp | Compositions and methods for treating allergic and inflammatory conditions with cough |
WO2001074341A2 (en) * | 2000-03-30 | 2001-10-11 | Schering Corporation | Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
WO2002096406A1 (en) * | 2001-05-25 | 2002-12-05 | Ssp Co., Ltd. | Medicinal compositions |
WO2003068203A1 (en) * | 2002-01-30 | 2003-08-21 | Zentiva, A.S. | Use of a combination of a non-steroidal anti-inflammatory agent and guaifenesin for the treatment of acute pain |
US8318709B2 (en) | 2002-06-14 | 2012-11-27 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
US9259428B2 (en) | 2002-06-14 | 2016-02-16 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
US9901585B2 (en) | 2002-06-14 | 2018-02-27 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
US8937057B2 (en) | 2002-06-14 | 2015-01-20 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
US8933060B2 (en) | 2002-06-14 | 2015-01-13 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
US8304405B2 (en) | 2002-06-14 | 2012-11-06 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
EP1572206A2 (en) * | 2002-12-18 | 2005-09-14 | Wyeth | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
US7863287B2 (en) | 2002-12-18 | 2011-01-04 | Wyeth Llc | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
AU2003301188B2 (en) * | 2002-12-18 | 2009-07-02 | Pf Consumer Healthcare 1 Llc | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
EP1572206A4 (en) * | 2002-12-18 | 2007-07-18 | Wyeth Corp | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
US6979689B2 (en) | 2002-12-20 | 2005-12-27 | Pediamed Pharmaceuticals, Inc. | Compositions and methods for treating upper respiratory congestion |
WO2004058236A1 (en) * | 2002-12-20 | 2004-07-15 | Pediamed Pharmaceuticals, Inc. | Compositions and methods for treating upper respiratory congestion |
DE102007000521A1 (en) | 2007-10-18 | 2009-04-23 | Renate Conrad | cough preparation |
EP2050435A1 (en) | 2007-10-18 | 2009-04-22 | Renate Conrad | Cough mixture |
GB2475359A (en) * | 2009-11-11 | 2011-05-18 | Biocopea Ltd | A compound for use in treating a fulminant respiratory disorder |
WO2016063057A1 (en) * | 2014-10-21 | 2016-04-28 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
US20170304296A1 (en) * | 2014-10-21 | 2017-10-26 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
WO2017062997A1 (en) * | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
WO2022119431A1 (en) * | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases |
Also Published As
Publication number | Publication date |
---|---|
US4749722A (en) | 1988-06-07 |
CA1258430A (en) | 1989-08-15 |
ZA852485B (en) | 1985-11-27 |
EP0180597B1 (en) | 1992-03-04 |
US4920149A (en) | 1990-04-24 |
US4552899A (en) | 1985-11-12 |
US4749721A (en) | 1988-06-07 |
US4619934A (en) | 1986-10-28 |
US4749720A (en) | 1988-06-07 |
ATE72989T1 (en) | 1992-03-15 |
US4738966A (en) | 1988-04-19 |
US4839354A (en) | 1989-06-13 |
AU2029195A (en) | 1995-08-03 |
DE3585495D1 (en) | 1992-04-09 |
JPS61501913A (en) | 1986-09-04 |
US4749723A (en) | 1988-06-07 |
US4749711A (en) | 1988-06-07 |
US4552899B1 (en) | 1992-10-20 |
US4749697A (en) | 1988-06-07 |
EP0180597A1 (en) | 1986-05-14 |
AU589554B2 (en) | 1989-10-19 |
JP2848556B2 (en) | 1999-01-20 |
AU4120085A (en) | 1985-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU589554B2 (en) | Nsaids in cough/cold mixtures | |
US5025019A (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
EP0311677B1 (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
US4985459A (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same | |
AU576825B2 (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same | |
EP0316434B2 (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
US4871733A (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
PT1518555E (en) | Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor | |
US20120064152A1 (en) | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same | |
US6900189B2 (en) | Analgesic and glucosamine compositions | |
US4683243A (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same | |
US4755532A (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same | |
CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
US4840962A (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
US4585783A (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same | |
US4906625A (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramine and metyhods of using same | |
EP0555411A1 (en) | Dextromethorphan antitussive compositions | |
AU738274B2 (en) | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs | |
ZA200500064B (en) | Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib. | |
WO1997048390A1 (en) | Analgesics combining acetaminophen with meclizine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1985901895 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1985901895 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1985901895 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1985901895 Country of ref document: EP |